Collegium Pharmaceutical (NASDAQ:COLL)‘s stock had its “buy” rating reissued by equities research analysts at William Blair in a report released on Tuesday, TipRanks reports. William Blair also issued estimates for Collegium Pharmaceutical’s Q1 2020 earnings at $0.08 EPS, Q2 2020 earnings at $0.17 EPS, Q3 2020 earnings at $0.33 EPS and Q4 2020 earnings at ($0.02) EPS.
A number of other brokerages also recently weighed in on COLL. Zacks Investment Research raised shares of Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a report on Thursday, August 8th. ValuEngine raised shares of Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. BidaskClub raised shares of Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a report on Tuesday, August 13th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $24.00 price objective (down from $35.00) on shares of Collegium Pharmaceutical in a report on Thursday, August 8th. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $24.33.
Shares of NASDAQ:COLL traded down $0.01 during midday trading on Tuesday, reaching $11.63. The company had a trading volume of 378,309 shares, compared to its average volume of 360,442. The company’s 50 day moving average price is $11.36 and its 200 day moving average price is $13.12. The company has a current ratio of 1.25, a quick ratio of 1.20 and a debt-to-equity ratio of 0.23. The stock has a market cap of $391.10 million, a P/E ratio of -9.77 and a beta of 0.52. Collegium Pharmaceutical has a 52-week low of $10.01 and a 52-week high of $19.83.
Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Wednesday, August 7th. The specialty pharmaceutical company reported ($0.14) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.05. The company had revenue of $75.04 million for the quarter, compared to the consensus estimate of $75.77 million. Collegium Pharmaceutical had a negative net margin of 7.45% and a negative return on equity of 26.10%. The firm’s quarterly revenue was up 2.7% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.40) EPS. Research analysts forecast that Collegium Pharmaceutical will post -0.36 EPS for the current fiscal year.
In other Collegium Pharmaceutical news, Director David Hirsch sold 22,106 shares of the company’s stock in a transaction dated Thursday, August 29th. The shares were sold at an average price of $11.65, for a total transaction of $257,534.90. Following the sale, the director now directly owns 64,223 shares of the company’s stock, valued at $748,197.95. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Michael Thomas Heffernan sold 25,000 shares of the company’s stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $11.26, for a total transaction of $281,500.00. Following the sale, the director now directly owns 132,069 shares in the company, valued at $1,487,096.94. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 49,963 shares of company stock worth $574,205. Insiders own 8.08% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in COLL. BNP Paribas Arbitrage SA increased its position in shares of Collegium Pharmaceutical by 67,855.6% during the first quarter. BNP Paribas Arbitrage SA now owns 6,116 shares of the specialty pharmaceutical company’s stock valued at $93,000 after buying an additional 6,107 shares during the period. State Board of Administration of Florida Retirement System increased its position in shares of Collegium Pharmaceutical by 147.7% during the first quarter. State Board of Administration of Florida Retirement System now owns 35,562 shares of the specialty pharmaceutical company’s stock valued at $538,000 after buying an additional 21,203 shares during the period. Acadian Asset Management LLC bought a new stake in shares of Collegium Pharmaceutical during the first quarter valued at about $2,074,000. Alambic Investment Management L.P. bought a new stake in shares of Collegium Pharmaceutical during the first quarter valued at about $852,000. Finally, DekaBank Deutsche Girozentrale increased its position in shares of Collegium Pharmaceutical by 22.2% during the first quarter. DekaBank Deutsche Girozentrale now owns 13,200 shares of the specialty pharmaceutical company’s stock valued at $221,000 after buying an additional 2,400 shares during the period. Hedge funds and other institutional investors own 92.08% of the company’s stock.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.
Featured Story: Cost of Equity For A Business, Investors
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.